Thursday, October 29, 2020

CORRECTION: Free 1-hr "Live" CME/AAPA/CNE/CPE/CPT/CPH Webinar on: Orange Book: Frequently Asked Questions and Answers - Drug Information Update

If your email program has trouble displaying this email, view it as a web page.

FDA Center for Drug Evaluation and Research Division of Drug Information

Date Correction: This webinar will take place on November 16, 2020.

 

FDA's Division of Drug Information is presenting a series of continuing education (CE) webinars targeting the needs of all health care professionals.

FDA Drug Topics: Orange Book: Frequently Asked Questions and Answers

November 16, 2020

Time: 1:00 pm to 2:00 pm (EDT)

Register

After registering, you will receive a calendar invitation with details on how to join the online meeting.

An email will be sent to all participants by the next business day with instructions on how to claim CE and a copy of the presentation slides!

Activity Outline

Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar is intended to assist stakeholders in utilizing the Orange Book. It will address some of the most frequently asked questions that the FDA has received from interested parties regarding the Orange Book.

References:

Series Objectives:

  • Explain how to utilize FDA's drug information, medication safety resources, and regulatory guidance, to improve delivery of patient care and optimize outcomes.
  • Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.

Learning Objectives: After completion of this activity, the participant will be able to:

  1. Utilize the Orange Book to identify therapeutically equivalent products
  2. Identify the regulatory requirements for submission of patent information to the FDA
  3. Recognize the statutory requirements for the movement of drug products between the active and discontinued sections of the Orange Book and the timing for publication
  4. Employ the Orange book website to locate relevant regulatory information

Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, certified public health professionals, other health care professionals, and students.

Schedule:
1:00 pm - 2:00 pm – FDA Drug Topics: Orange Book: Frequently Asked Questions and Answers, presented by Captain Kendra Stewart, Supervisor of the Orange Book Staff within the Office of Generic Drug Policy (OGDP) in FDA's Center for Drugs and Evaluation (CDER).

Continuing Education:

Accreditation:

IPCE Credit

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

IPCE Credit

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-20-006-L04-P, and ACPE Universal Activity Number JA0002895-0000-20-006-L04-T for 1.00 contact hour(s).

CNE
FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

PA AAPA Category 1 CME

This activity is designated for 1.00 AAPA Category 1 CME credits. FDA Center for Drug Evaluation and Research has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.

CPH
Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for receiving CE Credit:

Physicians, physician assistants, nurses, pharmacists, pharmacy technicians, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation survey via the CE Portal (ceportal.fda.gov). Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacy participants: Pharmacists and pharmacy technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit:

Attendees have 14 days from the last day of the activity to log in, attest to your attendance, and complete the required evaluation survey, to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the activity to obtain their CE credit.

Disclosure:

Faculty:

  • Stewart, Kendra, Supervisor, FDA/CDER/OGD/OGDP/DLRS - nothing to disclose.

Planning Committee:

  • Burke, Kara, PharmD, Team Leader/Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose 

  • Cao, Christian, MPAS, PA-C, Safety Evaluator Team Leader, FDA/CDER/OSE/DPV - nothing to disclose

  • DeFronzo, Kimberly, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose 

  • Kapoor, Rama, MD, Medical Officer, FDA - nothing to disclose 

  • Navin, Lesley, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose 

  • Nguyen-Chu, Thanh Tam, PharmD, Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose

CE Consultation and Accreditation Team:

  • Thompson, Lisa, MSHA, MBA, CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
  • Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov.

To learn more about future dates and registration, please visit: www.fda.gov/DDIWebinars


This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration · 
10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA
GovDelivery logo

No comments:

Post a Comment